In a landmark decision, the FDA has approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes. This approval expands the use of the popular injection and could revolutionize the treatment of these interconnected conditions.
The Food and Drug Administration (FDA) has granted approval for Novo Nordisk 's Ozempic to be used for patients diagnosed with both chronic kidney disease and diabetes. This expansion marks a significant development in the treatment landscape for these interconnected conditions.
The FDA's decision allows Ozempic to be utilized in reducing the risk of kidney disease progression, kidney failure, and cardiovascular disease-related death in individuals suffering from both chronic kidney disease and diabetes. The approval could revolutionize the way doctors manage chronic kidney disease, a condition characterized by a gradual decline in kidney function and a leading cause of death in the United States. Around 37 million American adults live with chronic kidney disease, and a significant proportion of Type 2 diabetes patients also have this condition. Chronic kidney disease can lead to complications such as an increased risk of cardiovascular problems and mortality. 'All chronic kidney disease is progressive,' explained Stephen Gough, Novo Nordisk's global chief medical officer, highlighting the relentless nature of the disease's progression. 'It's a year-on-year, relentless decline in renal function,' he stated, referring to the kidney's vital role in filtering waste from the blood. Gough emphasized that as chronic kidney disease advances to end-stage kidney disease, patients require dialysis treatments or kidney transplants to maintain waste removal from their blood. Both these options are burdensome, and the mortality rate among patients with end-stage kidney disease, particularly from cardiovascular disease, is 'very high,' according to Gough. This approval underscores the significant health benefits of GLP-1s, a class of blockbuster drugs used for diabetes and weight management, extending beyond blood sugar regulation and appetite suppression. In a clinical trial, Ozempic demonstrated a 24% reduction in the risk of severe kidney outcomes, including kidney failure, decline in kidney function, or death from kidney or heart causes, compared to a placebo in diabetic patients with chronic kidney disease. Furthermore, Ozempic users experienced slower kidney function decline, an 18% decrease in the risk of major cardiovascular events like heart attacks, and a 20% reduction in the risk of death from any cause compared to the placebo group. Ozempic also cut the risk of cardiovascular-related deaths by 29%. 'We know that, unfortunately, cardiovascular disease and chronic kidney disease just go hand in hand,' Gough stated. He added that current treatment approaches for early-stage chronic kidney disease primarily focus on reducing cardiovascular risk factors by addressing blood pressure.While the rate of serious adverse side effects was 49.6% in Ozempic users, it was lower than the 53.8% seen in the placebo group. There was a slightly higher discontinuation rate among Ozempic patients due to gastrointestinal side effects commonly associated with GLP-1s, such as nausea and vomiting. Novo Nordisk concluded the phase three trial in October, a year ahead of schedule, due to positive results.The company's announcement at the time caused a decline in the share prices of kidney dialysis companies. Novo Nordisk views this FDA approval as a significant step forward in addressing the intertwined nature of chronic kidney disease and diabetes. 'From my point of view as a doctor, you don't get in isolation,' Gough said. 'These illnesses, unfortunately, co-segregate. They cluster within the same individuals. So if you have a medicine that can target each of these co-morbidities in one injection, then you're addressing what really matters to the patient,' he emphasized
Ozempic Chronic Kidney Disease Diabetes FDA Approval Novo Nordisk GLP-1S Cardiovascular Disease Kidney Failure
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA Approves Ozempic for Chronic Kidney Disease and Diabetes, Expanding Treatment OptionsThe Food and Drug Administration (FDA) has approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, marking a significant advancement in the treatment of these interconnected conditions. This approval could transform how doctors manage chronic kidney disease, a major health concern in the United States.
Read more »
Ozempic Approved By FDA For Kidney Disease—In Ultra-Popular Drug’s Latest ApprovalRegulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and strokes.
Read more »
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its useExpanded Ozempic approval in the U.S. could transform how doctors treat patients with chronic kidney disease, which involves a gradual loss of kidney function.
Read more »
FDA Proposes New Front-of-Package Nutrition Labels to Combat Chronic DiseaseThe FDA proposes a simplified nutrition label to help consumers make healthier food choices, focusing on saturated fat, sodium, and added sugars. The new label aims to complement existing nutrition facts and make it easier for consumers to identify healthier options.
Read more »
FDA Proposes Front-of-Package Nutrition Labels to Combat Chronic DiseasesThe U.S. Food and Drug Administration (FDA) has proposed a landmark initiative requiring front-of-package nutrition labels on most packaged foods. These 'Nutrition Info boxes' will use a simple color-coded system to highlight levels of saturated fat, sodium, and added sugars, empowering consumers to make healthier choices. The FDA hopes this move will reduce diet-related diseases and encourage food manufacturers to reformulate products with less harmful ingredients.
Read more »
FDA Approves Sale of Nicotine Pouches For First TimeThe FDA has authorized the sale of nicotine pouches, a decision that has been met with both support and concern. The agency states that these pouches are less harmful than traditional tobacco products, but there are worries about their potential appeal to teenagers.
Read more »